News

The Swiss Venture Capital Report 2025 highlights the dynamic growth of the Swiss venture capital market in the past year. BGPartner played a key role in multiple major transactions, advising on some of Switzerland’s largest financing rounds.

In particular BGPartner advised the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund Coöperatieve U.A. (EQT), and SR One on the two biggest financing rounds of 2024:

• Alentis TherapeuticsAG  – CHF 160 million (Series D financing round)
• Asceneuron AG – CHF 89 million (Series C financing round)

In addition, BGPartner was involved in other significant transactions, including the Series C extension of Memo Therapeutics AG and the USD 147 million Series B extension of Noema Pharma AG, advising co-lead investors Forbion Growth Opportunities Fund II Coöperatief U.A., Jeito S.L.P., and LSP 7 Coöperatief U.A. (EQT).

Another milestone was BGPartner’s advisory role for the main selling shareholders HBM Healthcare Investments AG, Novo Holdings, and Forbion in the USD 1.25 billion spin-off of Yellow Jersey Therapeutics AG, a subsidiary of Numab Therapeutics AG, to Johnson & Johnson.

These successful transactions highlight BGPartner's leading role in both legal advisory and negotiation matters for complex financing rounds and transactions. A special thanks goes to the exceptional team at BGPartner for their outstanding work.

Find the full Swiss Venture Capital Report 2025.

BGPartner – Mastering Law & Negotiation

We show you how to maximize your own negotiation performance.

On April 1 and 2, 2025, we will be holding the Inhouse Counsel Exclusive Seminar in collaboration with Prof. Dr. Uta Herbst and Prof. Dr. Markus Voeth from the Negotiation Academy Potsdam. In this exclusive seminar, participants will learn how to optimize the interface between law and negotiation and maximize their negotiation performance.

The seminar will take place at the FIFA Museum in Zurich and the number of places is limited. Further information can be found in our flyer. Registration via registration link.

We look forward to two exciting days on the subject of negotiation.

The countdown is on. Once again this year, we are proud to host a Vis Moot Court Trial Round incl. Negotiation Add-on. On February 20, 2025, we will have the privilege of welcoming the teams from the following universities: Berne, Zurich and Lausanne and as well as from ZHAW.

Negotiation skills are an integral part of BGPartner's DNA. Training in negotiation skills not only leads to better results in real life, but is also highly relevant for students for their future careers as successful lawyers.

In addition to the official Vis Moot Court Trial Round, BGPartner therefore offers an additional training round in which the teams can develop their negotiation skills. They will benefit directly from the input of our negotiation experts.

We look forward to seeing you there!

BGPartner has successfully advised Lafayette Mittelstand Capital on its acquisition of the majority stake in Diametal Group, a global leader in high-precision cutting tools, super abrasives and wear parts. The transaction, effective as of January 1, 2025, marks a significant step in Diametal’s continued growth and international expansion.

Lafayette Mittelstand Capital is a private investment company specializing in medium-sized enterprises in Europe, with a strong focus on supporting businesses with substantial growth potential. By acquiring the majority of the stake in Diametal Group, Lafayette Mittelstand Capital aims to provide the company with the strategic support needed to further strengthen its market position and pursue new opportunities.

The BGPartner team advising Lafayette Mittelstand Capital was led by Dr. Alain P. Röthlisberger (Partner) and further consisted of David Dalla Vecchia (Senior Associate). Their comprehensive legal guidance covered all transaction-related matters, ensuring the smooth execution of the acquisition.

This acquisition reflects BGPartner’s strong expertise in complex M&A transactions within the industrial sector and underscores its position as a trusted legal advisor for private equity and corporate clients.

Windward Bio Group Ltd, a Swiss-based private, clinical-stage, drug development company successfully launched with a USD 200 m Series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. 

Windward Bio Group Ltd committed to improving outcomes for people living with advanced immunological diseases. Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with potential in asthma and chronic obstructive pulmonary disease (COPD).

BGPartner advised OrbiMed and Novo Holdings on all Swiss legal matters and the negotiations of this Series A financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).